Navigation Links
New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
Date:5/5/2008

were dry mouth, somnolence,

sedation, and constipation. The incidence of serious AEs was <2.5% in

all groups.(4)

-- Study 12 (Poster # NR3-140) -- In a time-to-event, double-blind,

randomized-withdrawal, parallel-group, placebo-controlled study, 433

patients were randomized to SEROQUEL XR or placebo following open-label

stabilization for a minimum of 12 weeks. The SEROQUEL XR dose was

flexible-50 mg, 150 mg, or 300 mg once daily, based on the clinical

judgment of the investigator. The risk of an anxiety event was

significantly reduced for SEROQUEL XR compared with placebo, suggesting

increased time to the event (HR=0.19 [0.12, 0.31]; p<0.001). Twenty-two

(10.2%) SEROQUEL XR-treated patients and 84 (38.9%) placebo-treated

patients experienced an anxiety event. The most common adverse events

(AEs) (greater than or equal to 5% in the SEROQUEL XR group) during the

randomized phase was headache and nasopharyngitis. The incidence of

serious AEs (randomized phase) was <2% in both groups.(5)

About SEROQUEL XR

In 2007, SEROQUEL XR was approved in the U.S. for the treatment of schizophrenia in adult patients and for maintenance treatment of schizophrenia in adult patients. In January 2008, AstraZeneca announced the submission of two separate sNDAs to the FDA for SEROQUEL XR to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder. In February 2008, AstraZeneca filed a sNDA for SEROQUEL XR to seek approval for the treatment of MDD as monotherapy, adjunct therapy, and maintenance therapy. The FDA has not completed its review of these submissions.

IMPORTANT SAFETY INFORMATION SEROQUEL XR

SEROQUEL XR is indicated for the acute and maintenance treatment of schizophrenia. Patients should be periodically reassessed to determ
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
2. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
3. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
4. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
5. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
6. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
7. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
8. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
9. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
10. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
11. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2008)... Awareness and Bring Hope to Millions,of Children ...e/ -- 133 million children,across the globe are wi...disaster, civil war, and disease. SOS Children,s V...ek by calling attention to the needs of orphans,wo... to:, http://www.prnewswire.com/mnr/soschildrens...
(Date:10/9/2008)...s and Marketing Efforts to Accelerate ... PARK, Calif., Oct. 9 /- Evalve, Inc.... percutaneous repair of cardiac valves,has expand... appointment of,Sean Cleary as senior vice preside...ardson, as vice president of sales., "The additio...
(Date:10/9/2008)...titute, Navigenics, Affymetrix and,Microsoft team ... /- A consortium of health care,tech...a first-of-its-kind,research study to assess the b...ople who choose to receive such screenings to iden...iseases., Sponsored by Scripps Translational Scie...
(Date:10/8/2008)...re-USNewswire/ -- The facts are,overwhelming. Ever...b-Saharan Africa. More than 35,000,000 women, chil...ied of AIDS. The Foundation for Hospices,in Sub-Sa...eir families,find compassion and relief from suffe...ring initiative links African hospices and palliat...
Breaking Medicine Technology:Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 1Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 2Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 3Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 5Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 6Overuse of Opioids Barbiturates Boosts Chronic Migraine Risk 17140 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 2Migraines Frequency Influences Heart Attack Stroke Risk 17138 3Parents stricter with older kids to set example 3A game theory study 17136 1Parents stricter with older kids to set example 3A game theory study 17136 2
...h 20, 2007 /PRNewswire-FirstCall/ --,Alfacell Corp...l to,act as a potent payload in antibody conjugate...ion of the Handbook of Therapeutic,Antibodies. , I... Susanna,Rybak, Ph.D. summarizes preclinical resea... ONCONASE improves in a number of tumor,models, in...
...Enzyme Levels in Two Most Common Mutations, CRANBU...erapeutics, a biopharmaceutical company developing...al chaperones for the,treatment of a range of huma...resent the results of preclinical studies of,Plice...disease at,the of Medical Genetics (ACMG) annual m...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...reatment could help prevent future blood clots in ...mboembolism (VTE) affects approximately 2 million ...osis (blood clots common in the thigh and back) an...on in the lung). Despite progress in diagnosis and...
...ion for some patients with large liver tumors. The... //before using lasers to heat and destroy the tum...proves the overall survival of the patients. Radio...nduced thermotherapy (LITT) to heat tumors. The pr...
...on that can be fatal. It is defined as an obstruct... a blood clot, //which blocks a coronary artery. W...onary embolism, a new study shows a new treatment ...inister to patients than the current treatment. Ac...
...f the American Society of Therapeutic Radiology an...beam radiation may be what it takes to relieve pai...d to the bone. More than 160 hospitals and univers...were involved in a study of about 900 men and wome...
Other Medicine News:Health News:Extended Therapy for Blood Clots 2Health News:New Liver Tumor Treatment 2
...w XCD-SX910CR digital camera incorporates a Progre...excellent sensitivity (1280 (H) x 960 (V) SXGA. Wh...ask (commonly called a "Bayer filter") and outputs... converted to a color image on the computer. The c...
...661 is a monochrome " 1.3 Megapixel FireWire camer...s. Desgined to simplify real-time uncompressed vi...A661 provides uncompromising video and digital sti...-A661 is ideal for industrial inspection tasks inv...
...h acclaimed GT-CAPTURE digital camera photomicrogr...ers microscope such as Olympus, Leica, Nikon, and ...sferring images over the Internet easy and fast. F...ormance-proven Nikkor lens. The system records pho...
...0 is a superb stand-alone digital camera with netw...es from local or remote locations. Image acquisiti...amera operates independently or attaches directly ...o capture and transfer images. Sharing images in r...
Medicine Products: